ADRX Andrx

Andrx Corporation (NASDAQ:ADRX) today announced that it plans to issue its 2006 first quarter financial results press release and file its Form 10-Q on Thursday, May 4, 2006, after the market close. Andrx will then host a conference call on Friday, May 5, 2006, at 8:00 a.m. ET. This call is being webcast by CCBN and can be accessed at Andrx's web site at http://www.andrx.com. The webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at http://www.fulldisclosure.com or by visiting any of the investor sites in CCBN's Individual Investor Network. About Andrx Corporation We are a pharmaceutical company that: -- develops and commercializes generic versions of primarily controlled-release pharmaceutical products, as well as oral contraceptives and selective immediate-release products; -- distributes pharmaceutical products, primarily generics, which have been commercialized by others, as well as our own, primarily to independent and chain pharmacies and physicians' offices; and -- develops and manufactures pharmaceutical products for other pharmaceutical companies, including combination products and controlled-release formulations. Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "should", "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including but not limited to: whether Andrx will be able to satisfactorily resolve the Food and Drug Administration's (FDA) April 2006 Form 483 - List of Inspectional Observations, which sanctions, if any, the FDA may seek in connection with its decision to place Andrx in Official Action Indicated (OAI) status or after any current or future inspections, including without limitation sanctions relating to any failure to comply with current Good Manufacturing Practices requirements, and if and when the "hold" on the Company's ANDA approvals will be lifted, the Company's dependence on a relatively small number of products, licensing revenues, the timing and outcome of litigation and future product launches, government regulation, competition, manufacturing capacities, safety issues, output and quality processes, the potential loss of senior management and other key personnel, and the completion of our merger with Watson Pharmaceuticals, Inc. Andrx Corporation is also subject to other risks detailed from time to time in its filings with the U.S. Securities and Exchange Commission. Andrx disclaims any responsibility to update the statements contained herein. This release and additional information about Andrx Corporation are also available on the Internet at: http://www.andrx.com.